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ORIGINAL ARTICLE
Three different brain tumours evolving from a common origin
T Forshew1, P Lewis2, A Waldman2, D Peterson2, M Glaser2, C Brock2, D Sheer1 and PJ Mulholland3
Despite an improved understanding of the molecular aberrations that occur in glioblastoma, the use of molecularly targeted
therapies have so far been disappointing. We present a patient with three different brain tumours: astrocytoma, glioblastoma and
gliosarcoma. Genetic analysis showed that the three different brain tumours were derived from a common origin but had each
developed unique genetic aberrations. Included in these, the glioblastoma had PDGFRA ampliﬁcation, whereas the gliosarcoma had
MYC ampliﬁcation. We propose that genetic heterogeneity contributes to treatment failure and requires comprehensive assessment
in the era of personalised medicine.
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INTRODUCTION
Glioblastoma is among the most aggressive brain tumours,
affecting 3500 people per year in the UK.1,2 Signiﬁcant progress
has been made in unravelling the genetic changes driving
glioblastoma.3–5 Despite this, trials using therapies to target these
changes have thus far been disappointing.6–8 One potential
challenge to targeted therapy is tumour heterogeneity.
A functional heterogeneity has been shown for glioblastoma stem-
like cells with the demonstration that they can form endothelial cells
contributing to tumour neovasculature.9 Possibly of greater concern,
there is increasing evidence of genetic heterogeneity in tumours.
This was demonstrated in a recent study of clear-cell renal
carcinoma, where 63–69% of all somatic mutations identiﬁed by
exome sequencing could not be detected across all regions of the
tumour.10 We present a patient with three histologically different
brain tumours for whom we have performed genome-wide copy
number analysis along with TP53, IDH1 and IDH2 sequencing.
RESULTS
Case report
A 41-year-old male presented with weakness of the left arm and
leg, poor coordination and difﬁculty in swallowing. The initial
magnetic resonance imaging of the brain showed an enhancing
mass in the right basal ganglia. Signal abnormality on the
T2-dependent sequences extended into the right peduncle and
also into the right side of the pons. The patient was commenced
on dexamethasone 4mg orally three times daily. A stereotactic
biopsy of the right basal ganglia was performed and the
histological examination conﬁrmed a diagnosis of glioblastoma
with regions of both grade II and IV tumour. The patient was
treated with standard chemoradiation followed by three cycles of
adjuvant temozolomide but his disease progressed.11 The patient
died 5 months after starting second-line chemotherapy and 10
months from diagnosis.
Imaging and histopathology
At post-mortem, three separate areas of the brain tumour
were sampled, one area was from the central pons, one from
the right basal ganglia and one from the left frontal region.
The pontine lesion and right basal ganglia were part of the same
tumour mass. Histopathological examination revealed that the
pontine tumour was a glioblastoma (WHO grade IV), the right
basal ganglia tumour was a ﬁbrillary astrocytoma (WHO grade II)
and the left frontal tumour was a gliosarcoma (WHO grade IV).
Serial magnetic resonance imaging at diagnosis and during
treatment and the corresponding H&E sections showed three
regions of tumour: (i) glioblastoma, (ii) astrocytoma and (iii)
gliosarcoma (Figure 1).
Genetic analysis of three tumours
In order to investigate the genetics underlying the three
different histological groups, DNA from each tumour sample
was screened for copy number change and loss of heterozygosity
(LOH) using the Affymetrix 250K single-nucleotide polymorphism
arrays (Affymetrix, Santa Clara, CA, USA). In addition, the tumour
samples were analysed for mutations of TP53, IDH1 and IDH2.5,12
The results showed speciﬁc genetic changes common to all three
tumours, as well as changes unique to each tumour. A model of
tumour development based on DNA changes in the three tumours
is proposed (Figure 2). All three tumours contained the
TP53 missense mutation c.817C4T (p.R273C) (Figure 3a) but no
mutation of IDH1 or IDH2. Each of the three tumours contained
deletion of 9p23-21.3 encompassing CDKN2A and CDKN2B
(Figure 3b), deletion of 15q13.3-22.31 (Figure 3c) and LOH of
chromosomes 10, 17 and 19. The glioblastoma was characterised
by ampliﬁcation of 4q12 containing the receptor kinase genes KDR
(VEGFR), KIT and PDGFRA (Figure 3d) and gain of CDK4, the
astrocytoma by multiple rearrangements, whereas the gliosar-
coma by ampliﬁcation of 8q24.21 containing the oncogene MYC
(Figure 3e).
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DISCUSSION
The most signiﬁcant advance in the treatment of glioblastoma
has been the addition of temozolomide chemotherapy to radio-
therapy, but the median survival in treated patients is
14.6 months.11 There has been a focus on determining molecular
markers that determine response in individual patients.13–17
However, in designing trials with molecular targeted
agents, tumour heterogeneity has not been addressed. If the
target is not present throughout the tumour, how can the tumour
respond to the treatment?18
Gliobastomas have been subdivided into ‘primary’ and
‘secondary’ glioblastoma.19 The patients with primary
glioblastoma are older with frequent activating mutations in
EGFR. The secondary glioblastoma patients are younger and
have tumours containing TP53 mutation, which have developed
from lower grade tumours.12 More recently, this classiﬁcation
has been expanded based on genomic and expression
changes deﬁning four groups, with classical being deﬁned
by aberrations in EGFR, mesenchymal by NF1, proneuronal
by changes in PDGFRA and IDH1 and a neural group deﬁned by
neural markers.5,20,21
The glioblastoma in this case is deﬁned as a secondary,
proneural glioblastoma. This patient was typical of those
with proneural tumours as he was relatively young and had
poor survival despite aggressive treatment.20 Gliosarcoma is
distinguished histologically from glioblastoma by sarcomatous
differentiation of the blood vessels. This diagnosis is made
much less frequently than glioblastoma and the prognosis is
worse.22,23
The shared origin of these three tumours was demonstrated by
the identical p.R273C TP53 mutation and the patterns of deletions.
Deletion of 9p21.3 in tumours is common as this region contains
the important tumour suppressor gene CDKN2A.24,25 In this
case, the region is deleted in all three tumours and the
breakpoints for these deletions are the same. This would not be
expected unless all three tumours were derived from the same
origin. Again chromosome 15 contains a deletion with breakpoints
common to all three tumours. In addition, there was a deletion at
11q14.1 and LOH of chromosomes 10, 17 and 19.
However, all the three tumours had additional unique muta-
tions. The astrocytoma contained nonspeciﬁc changes in keeping
with the greater radiation exposure. The gliosarcoma had a
number of unique changes including ampliﬁcation of 8q24.21-
containing MYC. The glioblastoma had gain of CDK4 and
ampliﬁcation of the receptor tyrosine kinase (RTK) PDGFRA. Three
recent studies used FISH to investigate RTK gene ampliﬁcation in
glioblastoma. They demonstrated different subclones within the
same tumour with differing and mutually exclusive EGFR, MET and
PDGFRA ampliﬁcation.26–28
Pre-treatment + 5 months + 7 months H&E sections
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Figure 1. Serial magnetic resonance imaging and the corresponding H&E sections showing three regions of tumour in the same patient:
(i) glioblastoma, (ii) astrocytoma and (iii) gliosarcoma.
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This study raises questions over the current approach to
diagnosis, tumour classiﬁcation and therapies. We propose
that a greater understanding of genetic heterogeneity is required.
This will require more sensitive detection of mutations and
rearrangements, more complete genetic assessment of the
tumour mass and potentially, assessment of cell-free DNA
where biopsy is problematic, for example, from cerebrospinal
ﬂuid or blood plasma.29 This should be incorporated into a
new tumour classiﬁcation system and to guide the use of
therapy ideally to those lesions present throughout the tumour
burden. Alternatively, we will have to identify and target multiple
lesions.
MATERIALS AND METHODS
Ethics approval
At the request of the patient and his wife, following the patient’s death, a
post-mortem examination was carried out and samples from the brain
tumours were removed for research purposes. Approval for the use of
patient material in research was obtained from Riverside Research Ethics
Committee (RREC 3059 and RREC 3344).
Sample preparation
At post-mortem, samples were taken for histopathological analysis and the
remaining was stored at  80 1C.
Affymetrix 250K single-nucleotide polymorphism array analysis
Tumour DNA was analysed for structural variations using the
Affymetrix 250K Nsp array following standard Affymetrix protocols.
Affymetrix 250K Nsp results were analysed for copy number changes
and LOH using the Copy Number Analyser for GeneChip software
package.30 Tumour data was normalised against that of normal
male DNA. All copy number ﬁgures show data smoothed using a
running mean of 50 single-nucleotide polymorphisms. Regions of LOH
potentially masked by contaminating normal DNA were identiﬁed using
the AsCNAR algorithm.31
Sequencing
All exons of TP53 and exon 4 of both IDH1 and IDH2 (including the
mutational hotspots, R132 in IDH1 and R172 in IDH2) were sequenced for
mutations. Target exons were ampliﬁed by PCR from tumour DNA,
followed by bidirectional direct sequencing using the dideoxy chain
termination method on an ABI 3730 DNA Sequencer (Applied Biosystems,
Glioblastoma
Amplification of 4p14-q12 (including 
PDGFRA)
Gain of 12q14.1 (including CDK4)
Astrocytoma
Progenitor
TP53 mutation (p.R273C)
9p23-21.3 loss (including CDKN2A)
11q14.1 & 15q13.3-22.31 loss
5q34-35.3 loss 
chromosome 18 loss
3q gain
Chromosomes 10, 17 & 19 LOH
11p loss
11q gain
Gliosarcoma
8q24.21 amplification
(including MYC)
1p36.33-p31.1 &
4p16 gain
3p26.3-p21.31, 11q14.1-q25 &
13q21.33-q34 loss
Figure 2. Model of tumour development based on DNA changes in the three tumours. (Note: chromosome 7 demonstrates gain in the
gliosarcoma and astrocytoma and is rearranged in the glioblastoma. Chromosomes 2 and 5 are rearranged in the gliosarcoma).
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Foster City, CA, USA). Results were screened by eye using the Applied
Biosystems Sequence Scanner Software v1.0.
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Figure 3. Genetic analysis of the 3 tumours: (i) glioblastoma, (ii) astrocytoma and (iii) gliosarcoma. Panel (a) shows the TP53missense mutation
c.817C4T (p.R273C), this was present in all three tumours (astrocytoma shown here). Panel (b) shows the 9p23–21.3 loss including CDKN2A
and CDKN2B in all three tumours. Panel (c) shows the loss 15q13.3–15q22.31 in all tumours. Panel (d) shows a region of gain including 4q12 in
the glioblastoma only. Among the genes in this region are the receptor kinase genes KDR (VEGFR), KIT and PDGFRA. Panel (e) shows
amplification of 8q24.21 containing the oncogene MYC in the gliosarcoma.
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